Bulgarian 
Croatian
Czech 
Danish
Dutch
Estonian
Finnish
French
German
Greek
Hungarian
Icelandic
Italian
Latvian
Lithuanian
Maltese
Norwegian
Polish
Portuguese 
Romanian
Slovak
Slovenian
Spanish
SwedishArticle Contents
- 1. NAME OF THE MEDICINAL PRODUCT
- 2. STATEMENT OF ACTIVE SUBSTANCE(S)
- 3. LIST OF EXCIPIENTS
- 4. PHARMACEUTICAL FORM AND CONTENTS
- 5. METHOD AND ROUTE(S) OF ADMINISTRATION
- 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
- 7. OTHER SPECIAL WARNING(S), IF NECESSARY
- 8. EXPIRY DATE
- 9. SPECIAL STORAGE CONDITIONS
- 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
- 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
- 12. MARKETING AUTHORISATION NUMBER(S)
- 13. BATCH NUMBER
- 14. GENERAL CLASSIFICATION FOR SUPPLY
- 15. INSTRUCTIONS ON USE
- 16. INFORMATION IN BRAILLE
- 2. NAME OF THE MARKETING AUTHORISATION HOLDER
- 3. EXPIRY DATE
- 4. BATCH NUMBER
- 5. OTHER
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton
1.NAME OF THE MEDICINAL PRODUCT
Lamivudine Teva 100 mg
Lamivudine
2.STATEMENT OF ACTIVE SUBSTANCE(S)
Each
3.LIST OF EXCIPIENTS
4.PHARMACEUTICAL FORM AND CONTENTS
Blisters:
28
30
84
100
5.METHOD AND ROUTE(S) OF ADMINISTRATION
Read the package leaflet before use
Oral use
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Keep out of the sight and reach of children.
7.OTHER SPECIAL WARNING(S), IF NECESSARY
8.EXPIRY DATE
- Trizivir - abacavir (as sulfate) / lamivudine / zidovudine
- Zeffix - lamivudine
- Combivir - lamivudine / zidovudine
- Kivexa - abacavir / lamivudine
- Lamivudine teva pharma b.v. - lamivudine
Prescription drugs listed. Substance: "Lamivudine"
EXP
9.SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
11.NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
12.MARKETING AUTHORISATION NUMBER(S)
EU/1/09/566/001– 28 Tablets
EU/1/09/566/002 – 30 Tablets
EU/1/09/566/003 – 84 Tablets
EU/1/09/566/004 – 100 Tablets
13.BATCH NUMBER
Lot
14.GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription.
15.INSTRUCTIONS ON USE
16.INFORMATION IN BRAILLE
Lamivudine Teva 100 mg
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
- Pioglitazone teva - Teva B.V.
- Ribavirin teva - Teva B.V.
- Levetiracetam teva - Teva B.V.
- Telmisartan teva - Teva B.V.
- Zoledronic acid teva pharma - Teva B.V.
- Aerivio spiromax - Teva B.V.
Prescription drugs listed. Manufacturer: "Teva B.V."
Immediate packaging (blister foil)
1. NAME OF THE MEDICINAL PRODUCT
Lamivudine Teva 100 mg
Lamivudine
2.NAME OF THE MARKETING AUTHORISATION HOLDER
TEVA B.V.
3.EXPIRY DATE
EXP
4.BATCH NUMBER
Lot
5.OTHER
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Tablet container
1. NAME OF THE MEDICINAL PRODUCT
Lamivudine Teva 100 mg
Lamivudine
2. STATEMENT OF ACTIVE SUBSTANCE(S)
Each
3. LIST OF EXCIPIENTS
4. PHARMACEUTICAL FORM AND CONTENTS
Tablet container:
- Lamivudine teva pharma b.v. - J05AF05
- Epivir - J05AF05
- Zeffix - J05AF05
Prescription drugs listed. ATC Code: "J05AF05"
60
5. METHOD AND ROUTE(S) OF ADMINISTRATION
Read the package leaflet before use
Oral use
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Keep out of the sight and reach of children.
7. OTHER SPECIAL WARNING(S), IF NECESSARY
8. EXPIRY DATE
EXP
9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
12. MARKETING AUTHORISATION NUMBER(S)
EU/1/09/566/005 – 60 Tablets
13. BATCH NUMBER
Lot
14. GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription.
15. INSTRUCTIONS ON USE
16. INFORMATION IN BRAILLE
Comments
